The ubiquitin proteasome system and its implications for oncology;Das Ubiquitin-Proteasom-System und seine Bedeutung in der Onkologie

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 22, 2013, Pages 1178-1182

  Engel, K ^a   Bassermann, F ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

deubiquitylases; multiple myeloma; proteasomal inhibition; ubiquitin ligases; ubiquitin proteasome system

Indexed keywords

PROTEASOME; UBIQUITIN;

ONCOLOGY; REVIEW;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84878155635     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0033-1343110     Document Type: Review

References (36)

1. Bassermann F., Frescas D., Guardavaccaro D. et al. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell: 2008; 134 256 267 (Pubitemid 352010329)
2. Bassermann F., Pagano M. Dissecting the role of ubiquitylation in the DNA damage response checkpoint in G2. Cell Death Differ: 2010; 17 78 85
3. Bassermann F., von Klitzing C., Munch S. et al. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell: 2005; 122 45 57 (Pubitemid 40977939)
4. Busino L., Millman S. E., Scotto L. et al. Fbxw7alpha- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol: 2012; 14 375 385
5. Caligiuri M. A., Briesewitz R., Yu J. et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood: 2007; 110 1022 1024 (Pubitemid 47267442)
6. Dehan E., Bassermann F., Guardavaccaro D. et al. betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell: 2009; 33 109 116
7. Dey A., Seshasayee D., Noubade R. et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science: 2012; 337 1541 1546
8. Fernández-Sáiz V., Targosz B. S., Lemeer S. et al. SCF(Fbxo9) and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nat Cell Biol: 2013; 15 72 81
9. Frescas D., Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer: 2008; 8 438 449 (Pubitemid 351744963)
10. Haupt Y., Maya R., Kazaz A. et al. Mdm2 promotes the rapid degradation of p53. Nature: 1997; 387 296 299 (Pubitemid 27220766)
11. Jagannath S., Barlogie B., Berenson J. et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British journal of haematology: 2004; 127 165 172 (Pubitemid 39371809)
12. Keyomarsi K., Tucker S. L., Buchholz T. A. et al. Cyclin E and survival in patients with breast cancer. N Engl J Med: 2002; 347 1566 1575 (Pubitemid 35315837)
13. Lamm W., Kaufmann H., Raderer M. et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica: 2011; 96 1008 1014
14. Li M., Brooks C. L., Kon N. et al. A dynamic role of HAUSP in the p53-Mdm2 pathway. Molecular cell: 2004; 13 879 886 (Pubitemid 38438482)
15. Li M., Chen D., Shiloh A. et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature: 2002; 416 648 653 (Pubitemid 34406767)
16. Ludwig H., Beksac M., Blade J. et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist: 2010; 15 6 25
17. Masuya D., Huang C., Liu D. et al. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J Pathol: 2006; 208 724 732
18. Nakayama K., Nagahama H., Minamishima Y. A. et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell: 2004; 6 661 672 (Pubitemid 38579350)
19. Obeng E. A., Carlson L. M., Gutman D. M. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood: 2006; 107 4907 4916 (Pubitemid 43882644)
20. Ohta T., Fukuda M. Ubiquitin and breast cancer. Oncogene: 2004; 23 2079 2088 (Pubitemid 38496737)
21. Oliner J. D., Kinzler K. W., Meltzer P. S. et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature: 1992; 358 80 83
22. Popov N., Wanzel M., Madiredjo M. et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol: 2007; 9 765 774 (Pubitemid 47019463)
23. Richardson P. G., Sonneveld P., Schuster M. W. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. The New England journal of medicine: 2005; 352 2487 2498 (Pubitemid 41007864)
24. Sanada M., Suzuki T., Shih L. Y. et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature: 2009; 460 904 908
25. Sargin B., Choudhary C., Crosetto N. et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood: 2007; 110 1004 1012 (Pubitemid 47267440)
26. Scheffner M., Huibregtse J. M., Vierstra R. D. et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell: 1993; 75 495 505 (Pubitemid 23335075)
27. Schwickart M., Huang X., Lill J. R. et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature: 2010; 463 103 107
28. Soucy T. A., Smith P. G., Milhollen M. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature: 2009; 458 732 736
29. Strohmaier H., Spruck C. H., Kaiser P. et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature: 2001; 413 316 322 (Pubitemid 32905853)
30. Su Y., Fu C., Ishikawa S. et al. APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase. Mol Cell: 2008; 32 652 661
31. Vassilev L. T., Vu B. T., Graves B. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science: 2004; 303 844 848 (Pubitemid 38174664)
32. Wang Q., Moyret-Lalle C., Couzon F. et al. Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene: 2003; 22 1486 1490 (Pubitemid 36390597)
33. Welcker M., Clurman B. E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature reviews Cancer: 2008; 8 83 93 (Pubitemid 351161321)
34. Yang J. C., Haworth L., Sherry R. M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med: 2003; 349 427 434 (Pubitemid 36910021)
35. Yang Y., Li C. C., Weissman A. M. Regulating the p53 system through ubiquitination. Oncogene: 2004; 23 2096 2106 (Pubitemid 38496739)
36. Zhang C., Cai T. Y., Zhu H. et al. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther: 2011; 10 1264 1275